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ABSTRACT 
The link between infection and hyperalgesia has been determined using mainly 
lipopolysaccharide, which is a bacterial antigen. The relationship between viral infection 
and hyperalgesia has yet to be fully characterized, with current models of virus-induced 
hyperalgesia being based on infections by specific neurotrophic viruses. Therefore, the 
aim of this series of studies was to develop a general model of virus-induced hyperalgesia 
by injecting a pyrogenic and non-pyrogenic dose of Poly I:C, a synthetic, double-stranded 
ribonucleotide that is similar to the double-stranded ribonucleotides produced by almost 
all viruses, into rats’ tails.  
 
To identify a pyrogenic and non-pyrogenic dose of Poly I:C, male Sprague Dawley rats 
were injected subcutaneously in the tail either with saline (n=8) or  100 µg.kg-1 (n=8) or 
1000 µg.kg-1 (n=8) Poly I:C. Only rats that received 1000 µg.kg-1 Poly I:C developed 
fever. Subsequently, in a separate experiment, tail withdrawal latencies to noxious 
thermal (49° water) and mechanical stimuli (4N blunt force) were recorded for six days 
after subcutaneous injection of 100 µg.kg-1 or 1000 µg.kg-1 Poly I:C or saline in male 
Sprague Dawley rats. I also took skin tissue samples from the site of injection to 
determine the histological changes that occur after Poly I:C injection. Thermal 
hyperalgesia was not elicited by Poly I:C injection. However, biphasic mechanical 
hyperalgesia developed in the animals receiving 100 µg.kg-1 Poly I:C, and sustained 
mechanical hyperalgesia, that lasted for four days, was evident in animals injected with 
1000 µg.kg-1 Poly I:C. Mild sustained inflammation, at the injection site of both doses of 
Poly I:C, was present even after the hyperalgesia had subsided.  
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This study provides evidence for a novel model of virus-induced hyperalgesia that is 
applicable to most cutaneous viral infections. More importantly, this model can be used 
to further our understanding of the mechanisms that underlie virus-induced pain. 
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1.1. Pain in viral infections 
1.1.1. Pain: a brief overview 
 
Pain, which is multidimensional in nature, is known to be an unpleasant sensory or 
emotional experience that may be associated with tissue damage (Blackburn-Munro 
2004; Kandel et al. 2000; Woolf 2004). There are four types of pain, namely, nociceptive, 
inflammatory, neuropathic and functional pain (Woolf 2004). Before proceeding with my 
discussion on virus-indiced pain, I shall briefly discuss the basic mechanisms underlying 
nociceptive and inflammatory pain; a discussion of neuropathic and functional pain is 
beyond the scope of this dissertation. Nociceptive pain is defined as the detection of 
noxious stimuli, such as noxious heat, cold, mechanical and chemical stimuli, by specific 
nociceptive nerve endings, resulting in a reflex withdrawal or reaction to the noxious 
stimulus. It is the population of thinly myelinated peripheral nerves called A-delta and 
unmyelinated C-fibres that are responsible for transmitting nociceptive information from 
the periphery to the central nervous system.  The transducer ion channels for these fibres 
are gated by temperature, chemical ligands and mechanical shearing forces (Woolf 2004). 
Nociceptive pain is acute and adaptive in that it contributes to the survival of the 
organism by guarding against tissue injury. Disabling of nociceptive pain leads to tissue 
damage that can manifest itself through self-induced mutilation (Dray 2005; Woolf 
2004).  
 
Compared to nociceptive pain, where the pain only occurs in response to a noxious 
stimulus, inflammatory, neuropathic and functional pain have different causes and are all 
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characterized by pain hypersensitivity (allodynia and hyperalgesia) and spontaneous pain 
(Devor 2005; McMahon 2005; Meyer 2005; Woolf 2004). Sensitization is a leftward shift 
of stimulus-response function in the magnitude of the neural response to stimulus 
intensity and occurs during inflammatory, neuropathic and functional pain (Meyer RA 
2005). Sensitization increases the probability that a stimulus will activate the target 
receptor or ion channel, by decreasing the threshold, augmenting the response to 
suprathreshold stimuli and ongoing spontaneous activity (Meyer RA 2005). Allodynia is 
pain caused by low-intensity innocuous stimuli, such as light touch, that usually do not 
cause pain. Hyperalgesia is characterized by an exaggerated and prolonged response to a 
noxious stimulus that is normally painful (Blackburn-Munro 2004; Woolf 2004).  
 
Inflammatory pain occurs during tissue damage, and typically resolves as tissue repair 
progresses. In some cases, the pain may outlast the period of repair, in which case 
inflammatory pain is maladaptive (Meyer RA 2005; Woolf 2004). Inflammation causes 
an enhanced response to suprathreshold mechanical stimuli, spontaneous activity and 
expanded receptor fields for both A-delta and C-fiber nociceptors, and reduced thresholds 
for the activation of nociceptors (Meyer RA 2005). Inflammation leads to the release of 
numerous chemicals, such as bradykinin, histamine, cytokines and prostaglandins from 
immunocompetent cells and injured cells, that may act directly or indirectly to alter the 
sensitivity of peripheral nerve terminals. Sensory fibers express three main classes of 
receptors affected by inflammatory processes, namely the G-protein-coupled receptors, 
ligand-gated ion channels and the cytokine receptors (Devor 2005; McMahon SB 2005; 
Meyer RA 2005; Woolf 2004). The principal determinant of peripheral nerve excitability 
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appears to be phosphorylation of voltage and ligand-gated membrane ion channels (Dray 
2005; Woolf 2004). 
 
To cause pain, inflammatory mediators recruit autonomic and sensory systems and cause 
the activation and sensitisation of the peripheral nociceptors. Some of these mediators 
directly activate nociceptors (e.g., bradykinins) by depolarization of the neuron (Martin et 
al. 2003; Meyer RA 2005; Woolf 2004). It is also the accumulation of various mediators 
together with tissue acidification acting synergistically that is suspected in the production 
of pain and hyperalgesia (Oprée and Kress 2000).Other mediators (e.g., prostaglandins) 
act indirectly via inflammatory cells, which in turn release algogenic agents, and also by 
changing the neuronal sensitivity and excitability of nociceptors to algogenic agents 
(Martin et al. 2003; Meyer RA 2005; Woolf 2004). The cytokines that are released during 
inflammation are suggested to excite nociceptors by activating receptor-associated 
kinases. These kinases phosphorylate ion channels on nociceptors facilitatoring signal 
transduction and increasing nociceptive sensitivity (Oprée and Kress 2000). Nociceptor 
hyperexcitability during inflammatory pain underlies the clinical signs of allodynia and 
hyperalgesia (Dray 2005; Woolf 2004).  
 
In addition to the influence peripheral inflammation has on the development of 
hypersensitivity to pain, there are changes in the way sensory information is processed by 
the central nervous system (CNS), which contributes to the hypersensitivity. Initially 
central sensitisation of nociceptive pathways is caused by increased nociceptor input into 
the spinal cord, but is sustained by changes in the dorsal horn neurons, which enhance the 
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release of neurotransmitters, and change synaptic receptor thresholds, kinetics (Martin et 
al. 2003; Meyer RA 2005; Woolf 2004). These changes are known to involve 
inflammatory mediators released by activated glial cells in the dorsal horn (Martin et al. 
2003; Meyer 2005; Wieseler-Frank et al. 2005; Woolf 2004). Central sensitisation 
manifests itself as allodynia and hyperalgesia and the spread of sensitivity to non-injured 
sites (secondary hyperalgesia) (Meyer RA 2005). For inflammatory pain, circulating 
cytokines maintain central sensitization, and are known to act on glial cells which they 
themselves can release other proinflammatory cytokines which result in a neuroexcitatory 
state (Meyer 2005; Watkins et al. 1995b; Wieseler-Frank et al. 2005). A cascade of 
events, in the dorsal horn, triggers the release of transmitters which change synaptic 
receptor threshold, kinetics and activation. Also, circulating cytokines in the blood may 
cause central sensitization by communicating to the brain via entering the 
circumventricular sites lacking the blood-brain barrier or via the vagal afferent (Watkins 
et al. 1995b; Wieseler-Frank et al. 2005).The secondary hyperexcitability, in the CNS, is 
observed due to peripheral inflammation and nerve injury causing neuroglia cells to 
release inflammatory mediators and cell regulators (Dray 2005; Woolf 2004). 
Inflammatory mediators can damage nerves and may begin to induce characteristics of 
neuropathic pain. 
 
Having summarised the basic principles of nociception and inflammatory pain 
hypersensitivity, in the remainder of this chapter I shall focus on pain caused by viral 
infections. In the following section, I shall outline the prevalence of three illustrative 
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examples of virus-induced pain, namely pain caused by Human immunodeficiency virus 
(HIV), Herpes simplex virus (HSV) and influenza virus infections.  
 
1.2. Models of Viral Pain 
 
In the previous section, I outlined the prevalence of pain caused by three viral diseases. In 
this section I shall provide information on animal models of viral pain that have been 
developed to gain a better understanding of mechanisms behind these pains, and 
therefore, potentially improve our treatment of viral pain. Rodents have been the most 
widely used animals in these models (Wang and Wang 2003). Similar structures in 
humans and in animal models, such as the brain, spinal cord and nerves, have been shown 
to be involved in the processing of nociception, and associated behaviours and therefore, 
animal models provide useful and essential systems to study and understand the 
pathophysiological mechanisms of human pain (Blackburn-Munro 2004). The two 
principal models of viral infections are models of HIV and Herpes virus infections. I shall 
now discuss animal models of each infection. 
 
1.2.1. Models of HIV-related pain 
 
The retrovirus HIV, being part of the Lentivirus subfamily, is a virus that thrives within 
cells of our immune system, ultimately causing immune system failure. By attaching to 
the CD4 receptor and CCR4/CXCR4 chemokine receptors, the virus infects CD4 T 
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lymphocytes and macrophages, and then uses these cells to replicate, ultimately 
destroying them resulting in the progression of the disease correlating with a decrease in 
CD4 T lymphocytes (Kramer-Hammerle et al. 2005; McArthur et al. 2005; Mogensen 
and Paludan 2001). Approximately 40 million individuals globally, are infected with 
HIV/AIDS with about 13000 people contracting the virus daily (WHO, 2005). Pain is 
prevalent throughout the course of HIV-infection and intensifies with the progression of 
the disease (Breitbart and Dibiase 2002; Breitbart et al. 1996; Del Borgo et al. 2001; 
Mogensen and Paludan 2001). The virus itself may cause pain, but secondary infections 
that occur during the progression of the disease and the pharmocotherapies, such as 
antiviral treatments, that are prescribed for the disease, also may cause pain (Joseph et al. 
2004). 
 
  A French survey of 314 patients, reported the incidence of pain in HIV infected 
individuals to be greater than 60% (Larue et al. 1993). Similar results also have been 
reported by studies in the United States of America, where 63% of ambulatory acquired 
immunodeficiency syndrome (AIDS) patients complained of persistent pain (Breitbart 
and Dibiase 2002). Other studies have reported pain prevalence in HIV infected people 
ranging from 50 to 90% (Del Borgo et al. 2001; O'Neill and Sherrard 1993). Sub-Saharan 
Africa has the worst HIV/AIDS epidemic in the world, with a third of the world’s HIV 
infected population living there (Robinson and Gazzard 2005). A recent study conducted 
in South Africa on terminally ill HIV-positive patients showed that 98% of patients 
reported pain, with pain being the number one complaint (Norval 2004). If approximately 
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60-80% of the 40 million individuals infected with HIV/AIDS globally experience pain, 
between 24-32 million people may be suffering from HIV-related pain. 
 
Body regions affected by HIV-related pains include the lower limbs as the most common 
site, followed by the mouth and throat region, then headaches and abdominal pain 
(Breitbart et al. 1998; Hewitt et al. 1997; Hirschfeld 1998; Penfold and Clark 1992).  
Human immunodeficiency virus has been known to cause pain by initiating neuropathies 
which occur in 15-50% of HIV-positive patients (Hewitt et al. 1997). A common 
neuropathy is the distal sensory neuropathy, caused by immunological dysfunction, and 
inflammatory demyelinating polyneuropathies, that are both acute (e.g., Guillain-Barré 
syndrome) and chronic (Breitbart et al. 1998; Luciano et al. 2003; O'Neill and Sherrard 
1993). Myelopathies and HIV dementia are some of the HIV neuropathies experienced 
by patients. For myelopathies, the exact mechanisms of how they cause pain are 
unknown but it is postulated that intralamellar vacuolation occurs in the spinal white 
matter (McArthur et al. 2005). Also, macrophages are implicated in the development of 
these pathologies by releasing pro-inflammatory cytokines, such as tumor necrosis factor 
(TNF), which act on the neurons directly or indirectly or act on glial cells (McArthur et 
al. 2005). Even though antiviral treatments have been developed for HIV which decrease 
disease morbidity and mortality (Andoh et al. 1995; Glare 2001; Sasaki 2003), antiviral 
treatments for HIV infection are known for adverse effects, such as pain (Cinti 2005; 
Joseph et al. 2004; Lee and Henderson 2001; Stenzel and Carpenter 2000; Newshan et al. 
2002). 
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Milligan and colleagues (2000) established a model of HIV-induced pain in rats. The 
researchers showed that thermal hyperalgesia and mechanical allodynia occur after 
intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope 
glycoprotein, gp120, which is an envelope protein that initiates cell entry by interacting 
with CD4 and chemokine receptors. By using two treatments (fluorocitrate, which 
selectively blocks astrocyte and microglia metabolism, and CNI-1493, a macrophage 
deactivator), they were able to show that the spinal cord glia may play a role in the pain 
states observed after administration of gp120 into the spinal cord.  The authors suggested 
that the gp120 portion of HIV-1 binds to and activates spinal glial cells, which mediate 
the gp120-induced hyperalgesia and allodynia. The role of inflammatory processes in the 
spinal cord as mediators of allodynia and hyperalgesia previously had been suggested by 
others from the same laboratory (Watkins et al. 1995a). Milligan and colleagues (2001) 
went onto investigate whether glial cells secrete pro-inflammatory cytokines which then 
mediate the gp120-induced pain state. Indeed, gp120 did induce sections of interleukin-1 
(IL-1) and TNF, and administering the respective cytokine blockers attenuated the pain 
(Milligan et al. 2001). The same group of investigators then showed that spinal cord nitric 
oxide, stimulated by intrathecal administration of gp120, synthesised by nitric oxide 
synthase-I, was in part responsible for the activation of the pro-inflammatory cytokines, 
by increasing mRNA levels, protein expression and protein released (Holguin et al. 
2004); blocking nitric oxide production with nitric oxide synthase inhibitors, abolished 
gp120-induced mechanical allodynia (Holguin et al. 2004). 
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The model used by Milligan and colleagues (2001), of injecting gp120 intrathecally, 
provides better understanding of how HIV, by producing inflammation in the CNS, may 
cause pain, but peripheral pathways also may be involved in HIV-related pain. 
Chemotactic cytokines, chemokines, released peripherally by immune cells, also have 
been implicated in producing gp120-induced pain. For HIV to gain enrty into immune 
cells it must bind CD4 receptors and chemokine coreceptors CCR4 and CXCR4 ( Oh et 
al. 2001). Activation of CCR4 and CXCR4 caused a central and peripheral increase in 
calcium ions, substance P release, neuronal excitation and resultant allodynia (Martin et 
al. 2003; Oh et al. 2001).  
 
The viral envelope protein gp120 also has been administered epineurally in rat sciatic 
nerve, causing allodynia and hyperalgesia (Herzberg and Sagen 2001). The 
administration of gp120 epineurally caused neuropathic pain and spinal gliosis, the latter 
being characterized by the excessive proliferation of neuroglia, especially in the 
interstitium. Glycoprotein 120 causes neuronal death by acting on neurons and glial cell 
release of neurotoxic substances, such as IL-1, which then disturb the neuronal calcium 
homeostasis and induce apoptosis (Viviani et al. 2001). Indeed, HIV-1 has been shown to 
cause sensory axonal degeneration through the induction of pro-inflammatory cytokines 
(Jones et al. 2005). Therefore, gp120 is able to produce hyperalgesia through peripheral 
and central mechanisms. 
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1.2.2. Models of herpetic pain 
 
The Herpes simplex virus (HSV) is phylogenetically old and has evolved with humans 
(Ellermann-Eriksen 2005). This co-evolution has enabled the virus to cope with the 
human immune defence system in many cases. The virus belongs to the 
Alphaherpesvirinae subgroup, has a rapid life cycle and establishes itself within sensory 
neurons (Ellermann-Eriksen 2005; Mogensen and Paludan 2001). Infection occurs with 
the cellular uptake of the viral particle via a heparin sulphate chain on a cellular 
proteoglycans receptor (Ellermann-Eriksen 2005; Mogensen and Paludan 2001). The 
virus spreads from cell to cell causing an acute immune response, but ultimately the virus 
establishes a latent infection in sensory neuron ganglia (Dalziel et al. 2004). Currently, 
the United States of America has a higher HSV prevalence, at about 22% of the 
population, than Europe (approximately less than 15%) (Smith and Robinson 2002). 
Herpes simplex virus global prevalence usually reaches 40% amongst teenagers by the 
age of 15 and rapidly increases to 80% older adults due to increased sexual activity 
(Smith and Robinson 2002).  Also, HSV prevalence rates in developing regions such as 
Sub-Saharan Africa and the Caribbean are substantially higher at 50% for adults older 
than 15 years of age. Furthermore, in other regions of the world, HSV infection is on the 
rise due to socio-economic factors such as poverty  (Ellermann-Eriksen 2005). Pain is 
reported during the primary infection, and during recurrent infections that occur when 
there is activation of the latent virus in sensory root ganglia (Dalziel et al. 2004; 
Ellermann-Eriksen 2005).  
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Herpetic pain states such as post-herpetic neuralgia have been estimated at about 500 000 
cases per year in the United States of America (Bowsher 1999), and about 200 000 cases 
per year in England even though this was thought to be a very conservative estimate 
(Bowsher 1999; Dalziel et al. 2004). Another study, that was conducted in a large double-
blind placebo-controlled clinical trial of acyclovir, an antiviral treatment for HSV 
infection, in the United Kingdom, reported that about 60% of HSV-infected people had 
pain in the form of neuralgia (Oster et al. 2005).  
 
 Primary infection can be produce more pain than that of secondary infections and may 
last clinically for three weeks (Dalziel et al. 2004; Mogensen and Paludan 2001). Besides 
fever and headaches, reactivation of latent HSV results in lesions occurring at areas 
innervated by infected nerves producing aching and burning sensations (Dalziel et al. 
2004; Sasaki 2003). Oster and colleagues (2005) showed that two thirds of subjects with 
post-herpetic neuralgia complained of their worst pain being moderate to severe, with 
half of the patients being in constant mild to severe pain (Oster et al. 2005). Also post-
herpetic neuralgia, which is classed as neuropathic pain, may last for more than three 
months with the pain impairing sleep, causing depression and social withdrawal (Dalziel 
et al. 2004). The mechanisms involving herpetic pain are being investigated but are still 
largely unknown. 
 
To understand the mechanisms of HSV-1 pain, rats were inoculated intradermally with 
HSV-1 in the hind limb and behavioural responses to noxious stimuli were examined 
(Andoh et al. 1995). Hypoalgesia, a decreased response to a painful stimulus, was 
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produced after administration of HSV-1. Andoh and colleagues (1995) were able to show 
the presence of paresthesia which was tested for by using the paw-pressure method. The 
authors postulated that the paresthesia may be caused by the virus disrupting the 
functioning of neurons. Another model for hyperalgesia and allodynia induced by HSV-1 
was established by Takasaki and colleagues (2000b), who showed that inoculation of 
mice with HSV-1, on the hindpaw, caused mechanical hyperalgesia and allodynia. In this 
study, the pain states peaked on day five and six post-inoculation, which coincided with a 
peak in HSV-1 DNA in the dorsal root ganglia. The hyperalgesia and allodynia were 
most likely a result of herpetic infection of sensory neurons and of HSV-1 propagation in 
the dorsal root ganglia, causing dysfunction of nociceptive sensory neurons (Takasaki et 
al. 2000b). Herpes simplex virus-1 inoculation also causes the release of cytokines and 
prostaglandins in the dorsal root ganglia, which probably contributed to the development 
of allodynia and hyperalgesia (Takasaki et al. 2000b; Eccles 2005).  
 
What may have also contributed to the allodynia and hyperalgesia was the percentage and 
type of infected sensory neurons and the continued production of prostaglandins 
(Takasaki et al. 2000a). In another model of herpetic pain, chronic varicella-zoster virus 
infection in rats caused both allodynia and hyperalgesia up to 33 days post-infection 
(Fleetwood-Walker et al. 1999).. The authors stated that immune-mediated damage at the 
site of injection, in the footpad, may have played a minor role in the causing hyperalgesia 
and allodynia, while the presence of varicellar-zoster virus in the dorsal root ganglia, 
which had correlated with the increased sensitivity to sensory stimuli, had probably been 
the main determinant of the pain hypersensitivity observed.  The authors did however 
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concede that the mechanisms by which varicellar-zoster virus infection caused the 
observed sensory changes were unknown. 
 
While the models of HIV and herpetic pain I have described provide useful information 
on the mechanisms of viral pain, these models are specific to particular viruses, which 
infect the nervous system, and therefore any information gathered from these models may 
only be applicable to the model investigated (Fleetwood-Walker et al. 1999; Milligan et 
al. 2000). Hence, a general model of virus-induced hyperalgesia, that is not limited to a 
particular neurotrophic virus, is needed so that the model may be applicable to most of 
the viral infections observed. For the model to be applicable to most viruses, if not all, the 
model should be based on a viral attribute that is common to most, if not all, viruses. 
Double-stranded RNA which is indistinguishable between live viruses in terms of the 
toxic response at the organism level (Majde et al. 1998), is produced at some stage of the 
viral life-cycle in most viruses. Indeed, even single-stranded RNA viruses and DNA 
viruses produce double-stranded (ds)RNA during infection of host cells (Majde et al. 
1998). In single-stranded (ss)RNA viruses, dsRNA is formed as one of the steps during 
replication and in DNA viruses, dsRNA are formed as complementary mRNA’s  (Carter 
and De Clercq 1974; Majde et al. 1998). 
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1.3. Polyinosinic:polycytidylic acid (Poly I:C) 
1.3.1. Characteristics of Poly I:C 
 
Poly I:C is a synthetic double-stranded polyribonucleotide, which is similar to viral 
polyribonucleotides (Majde et al. 1998). Poly I:C forms a deep, narrow A-form helix that 
is RNA nuclease resistant, which makes it more resistant to endonuclease and 
exonuclease degradation than other formulations of viral dsRNA analogues (Majde et al. 
1998). This nuclease resistance therefore gives Poly I:C more time to mediate its effects 
before it is cleared by the immune system. Poly I:C initially was used to induce interferon 
by activation of macrophages, which are the first line of defense of the host, which at the 
time was thought to have clinical importance and potential as an antiviral therapy 
(Chadha et al. 2004; Majde 2000). However, intense work focusing on the potential 
antiviral effects of Poly I:C, showed Poly I:C to be more toxic than therapeutic (Chadha 
et al. 2004; Majde 2000).  
 
Poly I:C and other dsRNA activate the immune system through Toll-like receptor 3 
(TLR3), which is a transmembrane signaling protein expressed as part of the innate 
immune system (Fujimoto et al. 2004; Sen and Sarkar 2005). These receptors may be 
responsible for activating signaling cascades within cells and triggering immune and 
inflammatory responses to combat infection. Toll-like receptor 3 uses the MyD88-
independent pathway to induce interferon and antiviral genes. When TLR’s are activated 
by viruses or dsRNA, they initiate the innate immune response by causing the release of 
various mediators which activate other TLR’s on dendritic cells causing the dendritic 
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cells to mature, which is needed for a T-cell response (Fujimoto et al. 2004; Sen and 
Sarkar 2005). Toll-like receptor 3 has been shown to be involved in infections in the 
mouse with cytomegalovirus, reovirus and influenza (Fujimoto et al. 2004; Sen and 
Sarkar 2005). Other viruses use different TLR’s other than TLR3, such as herpes simplex 
viruses (TLR9) and respiratory syncytial viruses (TLR4),which initiate different signaling 
pathways such as the JAK/STAT pathway, initiated by interferon receptor, and RIG-I 
pathway that is also initiated by the TLR3 independent pathway. These pathways 
culminate in the induction of a set of genes that are induced by dsRNA as well. Poly I:C 
induces the activation of the same transcription factors as other viruses that cause the 
induction of interferon (Fujimoto et al. 2004; Sen and Sarkar 2005).  
 
Interferon is believed to stimulate protein serine/threonine kinase, apoptosis of infected 
cells and activation of the 2-5A system (Castelli et al. 1998; Majde 2000; Samuel 2001). 
The active protein serine/threonine kinase affects viral multiplication within single cells 
by inhibiting mRNA translation through phosphorylation of initiation factor-2α (Castelli 
et al. 1998; Majde 2000; Samuel 2001). As a means of eliminating infected cells, 
interferon is believed to stimulate apoptosis in infected cells where generalized cellular 
RNA degradation occurs by a non-specific mechanism which translates into the shut 
down of translation and homeostatic mechanisms within the cell, therefore inducing cell 
death (Castelli et al. 1998; Majde 2000; Samuel 2001). The 2-5A system has also been 
implicated in antiviral mechanisms by raising 2-5A-dependent RNase and the 2’-5’ 
oligoadenylate synthetases (Castelli et al. 1998). The 2’-5’ oligoadenylate synthetase acts 
to stop viral replication by cleaving dsRNA (Hovanessian 1991). Interferon also acts on 
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the central nervous system by altering the electrophysiological activity of brain regions, 
by modulating opiate mediated structures by direct action, involved with pain suppression 
mechanisms (Dafny and Yang 2005). Besides Poly I:C stimulating interferon, Poly I:C 
also stimulates the secretion of various cytokines (e.g., IL-6 and TNF) and prostaglandins 
that are common to influenza and the Epstein-Barr viral infections (Fortier et al. 2004; 
Majde 2000; Mogensen and Paludan 2001; Eccles 2005), and induces fever, a hallmark 
of these two viral infections (Krohel et al. 1976). Poly I:C stimulates interferon 
production through the interferon regulatory factor-3, which is activated by 
seronine/threonine phosphorylation and leads to transcriptional activation of interferon 
genes (Mogensen and Paludan 2001; Samuel 2001). Interferon then causes the release of 
pro-inflammatory cytokine such as tumour necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β), and interleukin-6 (IL-6) (Kimura et al. 1994). The sequence of releasing 
secondary mediators is not known but several studies have speculated the process with 
interferon, IL-6, TNF-α and IL-1 acting on the hypothalamus and causing a fever 
(Chuang et al. 1990; Fortier et al. 2004; Krueger et al. 1988; Lindsay et al. 1969; Won 
and Lin 1988). 
 
1.3.2. Poly I:C-induced fever 
 
Like lipopolysaccharide (LPS), Poly I:C induces the acute-phase response in numerous 
species (Fortier et al. 2004; Kimura et al. 1994; Mogensen and Paludan 2001; Traynor et 
al. 2004). Experimentation in rabbits on Poly I:C-induced fever was done to identify 
whether the effects of Poly I:C observed in humans could be duplicated in rabbits. 
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Intravenously administration of Poly I:C caused adverse reactions in rabbits that were 
consistent with humans, namely fever and hypotension, and high levels of serum 
interferon (Gatmaitan et al. 1980). Hypotension particularly was of interest since it also 
occurred in humans but was never evident in other species that had been injected with 
Poly I:C such as monkeys and chimpanzees (Gatmaitan et al. 1980). Hypotension and 
serum levels of interferon were increased with intramuscular and subcutaneous 
administrations of Poly I:C (Gatmaitan et al. 1980). Poly I:C fever, induced by Gatmaitan  
and colleagues (1980) like LPS-induced fever, was biphasic in nature and was 
antagonized by non-steroidal anti-inflammatory agents such as ketoprofen.  
 
Won and colleagues (1988) went on to demonstrate that Poly I:C administration into the 
third ventricle or the pre-optic anterior hypothalamus caused a dose-dependent fever in 
rabbits. Hypothalamic administration of Poly I:C was more effective at inducing fever 
than the cerebroventricular route, thereby possibly showing that the site of Poly I:C 
febrigenic action resides in the pre-optic area of the anterior hypothalamus. The 
attenuation of fever in rabbits by indomethacin and ketoprofen suggested that Poly I:C-
mediated fever was mediated by prostaglandins (Won and Lin 1988). Lastly, Kimura and 
colleagues compared the acute-phase response induced in rabbits by injection of LPS and 
Poly I:C (Kimura et al. 1994). The authors found that LPS-induced fever to be highest 3 
hours after pyrogen administration and that the fever decreased after 6 hours, whilst Poly 
I:C fever was more extended and resolved only after 24 hours. The authors did not 
mention when the fever caused by Poly I:C peaked. The LPS and Poly I:C fevers were 
dose-dependent. Lipopolysaccharide and Poly I:C fever also differed by LPS failing to 
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induce interferon-α, unlike Poly I:C which did induce interferon-α, and that LPS was able 
to induce interleukin-1α and interferon-β more rapidly than Poly I:C (Kimura et al. 1994).  
 
There remains a lot of controversy about the exact mechanisms by which Poly I:C 
mediates fever and the fever response. Chaung and colleagues (1990) showed with the 
use of a somatostatin antagonist (SS-14) that somatostatin, in the rat hypothalamus, may 
mediate the fever induced by interferon or its inducer Poly I:C. Another study reported 
that Poly I:C may act to induce fever through the endogenous release of noradrenaline 
from the rat hypothalamus (Liu et al. 1989). Fortier and colleagues (2004) suggested that 
the induction of TNF-α, IL-1 and IL-6 are involved in the initiation of Poly I:C induced 
fever with IL-6 acting as the circulating signal to the brain. Fortier and colleagues (2004) 
injected rats intraperitoneally with 750 µg.kg-1 Poly I:C to create a maximum change in 
body temperature which caused a fever response that started 2 hours post-injection and 
was over 8 hours later. Liu and colleagues (1989) used 0.50 µg Poly I:C, 
intrahypothalamically in rats, whilst Katafuchi et al. (2003) using 3.0 mg.kg-1 of Poly I:C, 
injected intraperitoneally in rats, induced a slow-onset but long lasting fever that began 8 
hours after injection, peaked 5 hours post-injection and was still present 7 hours after the 
peak (Fortier et al. 2004; Katafuchi et al. 2003).  
 
Fever is associated with a whole suite of behavioural changes, one of them being a 
decrease in activity (Bluthe et al. 2000; Mitchell and Laburn 1997). Like LPS, Poly I:C 
has been shown to cause a decrease in cage activity (Fortier et al. 2004) and spontaneous 
voluntary activity, such as running wheel activity (Katafuchi et al. 2003). Besides Poly 
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I:C having an effect on activity, Poly I:C, like LPS, is known to cause a decrease in food 
intake and weight loss (Fortier et al. 2004). The authors implicated IL-6, TNF-α and 
interferon-α in mediating a decrease in food intake by their rats by acting on the satiety 
region.  
 
Because Poly I:C has been shown to mimic the febrile and several behavioural aspects of 
the acute-phase response to viral infection, and because it is not infective and convenient 
to use under normal laboratory safety conditions, I think that Poly I:C is a suitable 
molecule with which to study other sickness behaviour associated with viral infection, 
namely pain. It is possible then, that Poly I:C is a good choice to develop a model of 
virus-induced hyperalgesia. 
 
1.4. Infection and hyperalgesia 
 
In an effort to understand the complex relationship between infection and hyperalgesia, 
various models of hyperalgesia induced by bacterial antigens have been established. 
Systemic administration of LPS from Gram-negative bacteria has been shown to induce 
hyperalgesia (Mason 1993; Satyanarayana et al. 2004; Watkins et al. 1994a). The 
appearance of hyperalgesia in rats administered LPS has been shown to depend on the 
dose of LPS administered and the testing time for hyperalgesia after injection. For 
example, low doses of LPS (1 µg.kg-1) induced monophasic fever and hyperalgesia, but 
high doses of LPS (10 µg.kg-1 and 100 µg.kg-1) only induced hyperalgesia in the first 
phase of biphasic fever (Abe et al. 2001). Lipopolysaccharide induces the production of 
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inflammatory cytokines TNF-α, IL-1β and IL-6, which are part of the fever response, 
these cytokines also have been shown to sensitize nociceptors (Abe et al. 2001).  
 
In addition to the direct effects of these cytokines on nociceptors, infection-induced 
cytokine production also may produce hyperalgesia by stimulating vagal afferents.Vagal 
afferents have also been implicated in systemic TNF-α and IL-1β induced hyperalgesia 
(Morgan et al. 2004; Watkins et al. 1995a; Watkins et al. 1994a; Wieseler-Frank et al. 
2004).  The vagus nerve, which provides cytokine-to-brain communication, projects to 
the nucleus raphe magnus which is known to modulate nociception (Morgan et al. 2004; 
Watkins et al. 1994a). Subdiaphragmatic vagotomy blocks LPS (i.p.), TNF-α (i.p.) and 
IL-1β (i.p.) induced hyperalgesia (Morgan et al. 2004; Watkins et al. 1995a; Watkins et 
al. 1994a).  
 
Lastly, whether by humoral or neural mechanism, pro-inflammatory cytokines released 
during infection may ultimaltely produce prostaglandins in the pre-optic anterior 
hypothalamus. Prostaglandins, mainly prostaglandin E2, also are thought to mediate fever 
and hyperalgesia via the medial pre-optic region of the brain (Heinricher et al. 2004; 
Hosoi et al. 1997). Receptors for prostaglandin E-type are found within the pre-optic 
medial region (Heinricher et al. 2004; Hosoi et al. 1997). Application of prostaglandin E2, 
in the medial pre-optic region, has been shown to produce hyperalgesia (Heinricher et al. 
2004; Hosoi et al. 1997). Heinricher and colleagues (2004) postulated that the rostral 
ventromedial medulla, which may receive input from the pre-optic medial region, is 
involved in pain facilitation or inhibition via the use of “on and off” cells. Therefore, 
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prostaglandin E2 may activate the on-cells thereby facilitating the hyperalgesia observed 
and inhibiting the off-cells (Heinricher et al. 2004). 
 
Glial cells within the spinal cord have also been reported to be of importance in cytokine 
mediated hyperalgesia (Milligan et al. 2000; Wieseler-Frank et al. 2004; Wieseler-Frank 
et al. 2005). The cytokines act on the glial cells, which then modulate nociception. 
Functional disruption of spinal glia blocks allodynia and hyperalgesia. It is thought that 
the cytokines’ actions on the glia result in these glia signalling other glia in the spinal 
cord to release cytokines within the spinal cord. These spinal cytokines are believed to be 
important in causing the observed pain states (Wieseler-Frank et al. 2005).  
 
While the interaction between infection and hyperalgesia is clear, there is a lack of 
correspondence between fever and hyperalgesia. For example, Yabuuchi and co-workers 
(1996) found that at low doses of IL-1β, no fever was induced but the same doses caused 
hyperalgesia. At higher doses of IL-1β which are febrigenic, analgesia was produced 
(Yabuuchi et al. 1996). Other studies have also shown that fever and hyperalgesia 
induced by IL-1β are similarly dissociated by dose and vagotomy (Heinricher et al. 
2004). Hosoi et al (1997) also confirmed the dissociation of fever and hyperalgesia 
following prostaglandin E2 in the medial pre-optic region, with hyperalgesia obtained 
only at subpyrogenic doses. Further investigation is needed to understand the mechanism 
of cytokine induced hyperalgesia (Heinricher et al. 2004) 
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While the mechanisms mediating fever and sickness behaviour, in terms of hyperalgesia, 
in response to a bacterial challenge, particularly LPS administration, have been 
thoroughly investigated and reported on (Mitchell and Laburn 1997), the mechanisms 
mediating virally-induced hyperalgesia have yet to be fully elucidated. Even though a 
few viral-pain models exist, they potentially are too specific to that particular virus, and 
therefore any information obtained from these models will only be applicable to the 
model investigated. 
 
1.5. Aims 
 
 
In order to understand the underlying mechanisms of viral pain, improve the therapies 
that are being prescribed for viral pain, and to understand the complex relationship 
between viral infection and hyperalgesia, a general model of virus-induced hyperalgesia 
that is not limited to a particular virus is needed so that the model may be applicable to 
most of the viral infections reported. Since Poly I:C is a synthetic virus that is similar to 
double-stranded RNA which is produced by most, if not all viruses, it is a prime 
candidate in developing a general model of virus-induced hyperalgesia. The aims of this 
study was to establish a general model of viral hyperalgesia using both pyrogenic and 
non-pyrogenic doses of Poly I:C.  
 
 
 
 
 24 
 
 
 
 
Chapter 2 
Experiments 
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2. 1. General Methods 
 
2.1.1. Animals 
 
I used 83 male Sprague-Dawley rats that weighed 230-250g at the start of experiments. 
Animals were housed individually in cages at an ambient temperature of ~23ºC, and on a 
12:12 hour light/dark cycle (lights on at 07:00). Food and water were available ad 
libitum.  
 
2.1.2. Drug Preparations 
 
Stock solutions of polyinosinic:polycytidylic acid (Poly I:C, Sigma-Aldrich, USA) were 
prepared by dissolving appropriate amounts of the immunogen in sterile, pyrogen-free 
saline, such that 100 µg.kg-1 and 1000 µg.kg-1 Poly I:C could be administered 
intradermally in a 100 µl volume. Aliquots of these stock solutions were frozen at -20ºC, 
and fresh aliquots thawed immediately before Poly I:C injections. 
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2. 2. Experiment 1: Pyrogenic properties of poly I:C  
 
2.2.1. Introduction 
 
 
Since models of infection-induced hyperalgesia use bacterial pyrogens such as LPS, or 
cytokines released during bacterial infection, such as TNF-α and IL-1β (Yabuuchi et al. 
1996), where models of infection-induced hyperalgesia have found a dissociation 
between fever and hyperalgesia, a new model of virus-induced hyperalgesia also needs to 
encompass simulated febrile and non-febrile viral infections. Therefore, the viral 
challenge used will have to include both a pyrogenic and non-pyrogenic dose. Poly I:C is 
a synthetic viral double stranded RNA that has been used experimentally to simulate 
virally-induced infection. Poly I:C has been shown to be an appropriate viral challenge 
since the immune response mimics viral infections and is relatively reproducible (Fortier 
et al. 2004). However, the route of administration of Poly I:C can affect the febrile 
response (Fortier et al. 2004). Therefore, before testing for the presence of hyperalgesia 
after administering Poly I:C, I first needed to establish the pyrogenicity of Poly I:C 
administered subcutaneously. Then, by using a pyrogenic and non-pyrogenic dose of 
Poly I:C, I could later (2.3 Experiment 2) determine whether the link between fever and 
hyperalgesia during simulated viral infection is any different to that reported for 
simulated bacterial hyperalgesia.  
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2.2.2. Methods 
 
i) Measurement of body temperature  
 
Rats anaesthetized with ketamine (80 mg.kg-1) and xylazine (40 mg.kg-1) had sterile, 
wax-coated temperature-sensitive radio telemeters (Mini-Mitter, USA; Figure 1) 
implanted intraperitoneally seven days before the start of experimentation. Before 
implantation, telemeters were calibrated in a water bath against a high accuracy quartz-
crystal thermometer to an accuracy of 0.1ºC (Quat 100, Heraeus, Germany). The output 
frequency of each telemeter was monitored by a receiver plate (RTA 500, Mini-Mitter, 
USA) placed beneath each animal’s cage, and transmitted via a peripheral processor 
(Datacol-3, Mini-Mitter, USA) to a personal computer, where frequencies were converted 
to temperatures and recorded. Body temperature was recorded every fifteen minutes 
throughout the experiment.  
 
ii) Experimental procedure 
 
Rats were randomly injected intradermally in the tail either with saline and 100 µg.kg-1 
Poly I:C (n=7), or saline and 1000 µg.kg-1 Poly I:C (n= 6). All injections were 
administered midway down the length of the tail, on the dorsal surface, in rats restrained 
in transparent plastic restrainers. All injections took place between 08:15 and 08:45, and 
animals were released from the restrainers back into their home cages immediately after 
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injection. Saline and Poly I:C were injected in random order, with at least two weeks 
between injections. 
 
 
Figure 1. A temperature-sensitive radio telemeter which was inserted into the rat 
abdomen. 
 
iii) Data analysis 
 
All temperature data are expressed as mean (SD). Temperature data were analysed using 
a two-way ANOVA with treatment and time as main effects. To reduce the size of the 
model, hourly averages were used in the analysis (from one hour before injection until 
eight hours after injection). A Newman-Keuls post hoc test was used to compare hourly 
means when significant main effects or interactions were detected by the ANOVA using 
Statistica 5.5 (Statsoft, Inc., Tulsa, USA), was used for all statistical procedures, α=0.05. 
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2.2.3. Results 
 
Figure 2 shows changes in body temperature of rats injected intradermally with Poly I:C 
and saline. Restraint and injection of saline and 100 µg.kg-1 Poly I:C (Fig 2A) induced a 
stress hyperthermia in all animals, which lasted for approximately 30min after the 
injection (main effect of time: F(8,96) = 44.08, P < 0.001). This short-lived increase in 
body temperature is the stress hyperthermia associated with handling during injections 
and has been well documented. After the stress hyperthermia had subsided, no further 
significant changes in body temperature occurred, and at no time was there a significant 
difference in body temperature between the two interventions (main effect of 
intervention: F(1,12) = 2.09, P = 0.174;  interaction: F(8,96) = 1.20, P = 0.309). All animals 
injected with saline and 1000 µg.kg-1 Poly I:C (Fig 2B) also experienced a stress 
hyperthermia during restraint and injection. Injection of 1000 µg.kg-1 Poly I:C induced an 
increase in body temperature approximately an hour after the stress hyperthermia had 
resolved (main effects of time: F(8,80) = 5.83, P < 0.001; main effect of intervention: F(1,10)  
= 25.66, P < 0.001; interaction: F
 (8,80) = 8.42, P < 0.001). The increase in body 
temperature reached a peak amplitude of approximately 38.6ºC approximately four hours 
after injection of Poly I:C, and remained significantly elevated for three hours after the 
peak, thus confirming that I used a pyrogenic and a sub-pyrogenic dose of Poly I:C in the 
nociceptive component of the investigation. Body temperature of all rats returned to 
pretreatment levels 24h after the Poly I:C or saline administration. 
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Figure 2: Mean (SD) body temperature of rats injected intradermally either with saline 
and 100 µg.kg-1 Poly I:C (A, n = 7), or saline and 1000 µg.kg-1 Poly I:C (B, n = 6).  * P < 
0.05: saline versus 1000 µg.kg-1 Poly I:C. 
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2.2.4. Discussion 
 
I sought to find a pyrogenic and non-pyrogenic dose of Poly I:C, to use in the 
development of a Poly I:C-induced model of pain. Two doses of Poly I: C,100 and 1000 
µg.kg-1, that were injected intradermally on the dorsal surface of the rats’ tail, were used. 
I was able to induce a fever with the injection of 1000 µg.kg-1 Poly I:C. The 1000 µg.kg-1 
Poly I:C caused a monophasic fever, characterized by an increase in abdominal 
temperature that reached a peak of about 38.6°C and lasted about five hours. Twenty-four 
hours post injection, no differences in temperatures between saline and Poly I:C 
injections were observed. The injection of 100 µg.kg-1 Poly I:C did not cause a fever.   
 
Cytokines such as IL-1, IL-6, TNF-α and interferon are known to be induced by Poly I:C 
and have been implicated in mediating fever induced Poly I:C (Chuang et al. 1990; 
Fortier et al. 2004; Kimura et al. 1994; Liu et al. 1989; Luheshi and Rothwell 1996). 
These cytokines (IL-1, IL-6, TNF-α and interferon) also are known to be pyrogenic 
themselves and mediate their effects by direct and non-direct actions on the brain, 
particularly the pre-optic-anterior hypothalamus (Chuang et al. 1990; Luheshi and 
Rothwell 1996; Krueger et al. 1988; Won and Lin 1988). The exact sequence in which 
these cytokines are released is controversial however; interferon is thought to be the 
primary mediator that stimulates the production of IL-1, IL-6 and TNF-α (Chuang et al. 
1990; Luheshi and Rothwell 1996; Won and Lin 1988). Therefore, by showing that we 
have a pyrogenic and a non-pyrogenic dose of Poly I:C, which presumably induce 
different levels of inflammation at the site of inflammation, we have suitable doses of 
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Poly I:C to develop a generalized model of virus-induced pain. I have also shown a novel 
method of Poly I:C fever induction by intradermal injections of Poly I:C in the rats tail. 
 
2.3. Experiment 2: Hyperalgesic properties of Poly I:C 
2.3.1. Introduction 
 
Various animal models have been developed to understand the relationship between 
infection and hyperalgesia (Maier et al., 1993; Abe et al., 2001). Lipopolysaccharide 
(LPS) from Gram-negative bacteria has been shown to induce hyperalgesia (Mason 1993; 
Satyanarayana et al. 2004; Watkins et al. 1994a), which probably is linked to its 
induction of cytokine (Mason 1993; Satyanarayana et al. 2004; Watkins et al. 1994a),  
such as IL-1 and TNF-α release (Bianchi et al. 1998; Mason 1993; Morgan et al. 2004). 
The mechanisms implicated for most models involving LPS, or cytokines released after 
LPS inoculation, for the production of the hyperalgesia involve activation of 
subdiaphragmatic vagal afferents and more importantly, the synthesis of prostaglandins 
in the hypothalamus (Abe et al. 2001; Hosoi et al. 1997; Watkins et al. 1995a). However, 
the link between fever and hyperalgesia is complex, with non-febrile doses of pyrogens 
inducing hyperalgesia (Abe et al. 2001; Oka et al. 1994), and febrile doses of pyrogens 
not causing hyperalgesia (Morgan et al. 2004; Oka et al. 1994).  
 
However, the extensive research into fever and hyperalgesia has mainly been concerned 
with bacterial challenges with little attention given to viral fever and hyperalgesia. I have 
established a pyrogenic and a non-pyrogenic dose of Poly I:C, therefore the aim of the 
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second experiment was to determine whether administration of these doses of Poly I:C 
induced hyperalgesia. I also assessed the extent of peripheral inflammation, at the site of 
Poly I:C or saline administration and related this tissue inflammation to the hyperalgesia.  
 
2.3.2. Methods 
 
All tests of nociception took place with rats placed in transparent plastic restrainers that 
allowed free movement of the tail, but limited body movement. Before the start of 
experimentation, rats were accustomed to the restrainers for three hours a day on three 
consecutive days. On days of nociceptive testing, I placed the rats into restrainers 30 
minutes before we measured response latencies to noxious mechanical and thermal 
challenges. 
 
i) Noxious thermal challenge 
 
I used the method described by Gelgor and colleagues (1986) to test for the presence of 
hyperalgesia to a noxious heat stimulus in rats injected either with saline or Poly I:C. 
Briefly, rats’ tails were submerged into 49°C water until a co-ordinated motor response 
(tail-flick) was observed (Figure 3). The time elapsed between submergence and flicking 
of the tail was measured using a stopwatch. The average of three measurements, taken at 
least one minute apart, was recorded as the tail-flick latency. Exposure to 49ºC water was 
limited to 30 seconds to prevent tissue damage (Gelgor et al. 1986). Rats’ tails were 
immersed in 29ºC water for thirty minutes before measurements started, and between 
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measurements, to remove the confounding effect variations in tail-skin temperature has 
on tail-flick latency.  
 
 
 
 
 
 
 
 
 
 
Figure 3. The tail of the rat is immersed into 49°C water and the time taken to remove the 
tail is recorded using a stopwatch. 
 
ii) Noxious mechanical challenge 
 
I used the method described by Vidulich and Mitchell (2000) to test for the presence of 
hyperalgesia to a noxious mechanical stimulus in rats injected either with saline or Poly 
I:C. Briefly, a bar algometer (Halda RS, Sweden), which was placed transversely across 
the injection site, was used to deliver a static force of 4N to rats’ tails (Figure 4). The 
response latency from when the force was applied until the first sign of aversive 
behaviour, such as the animal attempting to turn around in its restrainer, vigorous 
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grooming and withdrawing its tail, was measured using a stopwatch. An average of three 
measurements, taken at least one minute apart, was recorded as the escape response 
latency. The mechanical challenge was terminated if the rat had not responded within 30 
seconds. 
 
 
Figure 4. The mechanical stimulus applied to the site of injection at a constant force of 
4N using a bar algometer. 
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iii) Experimental procedure 
 
Rats were injected either with saline (n = 8), 100 µg.kg-1 Poly I:C (n = 9), or 1000 µg.kg-1 
Poly I:C (n = 8). For five consecutive days before rats were injected response latencies to 
the noxious mechanical and thermal challenges were measured to obtain pre-injection 
withdrawal response latencies. On the sixth day, animals were injected intradermally with 
the assigned agent. Animals’ response latencies to the noxious thermal and mechanical 
challenges were then measured three hours after injection and daily thereafter for six 
days. Injections took place between 08:00 and 08:45, and nociceptive testing always took 
place between 08:15 and 12:00. The thermal stimulus always was applied before the 
mechanical stimulus, with at least 30 minutes separating exposure to the thermal and 
mechanical challenges (Vidulich and Mitchell 2000). 
 
iv) Histology 
 
In a separate experiment, three groups of 15 rats each were injected either with saline, 
100 µg.kg-1 Poly I:C, or 1000 µg.kg-1 Poly I:C. Three animals from each group were 
killed three hours, one day, four days and ten days after injection, and tail-skin sections 
(down to, but not including the fascia) were taken from the site of injection. Skin sections 
were fixed in 10% formalin and embedded in paraffin before been stained with 
haematoxylin and eosin. The sections then were examined, under a light microscope, by a 
histopathologist for the presence and severity of inflammation. The fixing and scoring of 
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the tissues was performed by a consultant pathologist (Dr. B Mitchell, MBBCh (FC) Path 
SA, Mansfield, UK). 
 
v) Data analysis  
 
All nociceptive data are expressed as mean percentage change in withdrawal response 
latency from the five-day average of pre-injection values. Repeated-measures ANOVA 
were used to detect for significant changes in nociceptive response latencies over the six 
days of the experiment. Zero percentage change from pre-injection values was included 
in these analyses as a control. When significant effects were detected by the ANOVA, 
one-sample t-tests were used to compare the percentage change in nociceptive response 
latency at each time interval to zero change (no effect of injection). A Bonferroni 
correction for multiple comparisons was made. To take the magnitude of the change in 
nociceptive response latency into consideration, only response latencies that were 
statistically significant from zero, and where the 95% confidence interval of the mean 
difference between zero change (no effect of injection) and the measured percentage 
change in response latency was at least a 20%, were considered biologically significant. 
These statistical analyses were performed using Prism 4.03 for Microsoft Windows 
(Graphpad Software, USA), with P < 0.05 considered significant. 
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2.3.3. Results 
 
i) Noxious thermal challenge 
 
Figure 5 shows percentage changes in tail-flick latencies to a noxious thermal challenge 
after injecting rats intradermally either with saline, 100 µg.kg-1 Poly I:C, or 1000 µg.kg-1 
Poly I:C. There were no significant changes in tail-flick latencies from pre-injection 
values after injection either of saline (F(7,7) = 1.58, P = 0.164) or 1000 µg.kg-1 Poly I:C 
(F(7,7) = 1.82, P = 0.104). For animals injected with 100 µg.kg-1 Poly I:C, there were 
significant variation in tail-flick latencies over time (F(7,8) = 5.57, P < 0.001), but post hoc 
tests and analysis of the confidence intervals failed to show any significant changes in 
tail-flick latencies from pre-injection values at each time interval. Across all groups, the 
mean percentage change in tail-flick latency never decreased by more than 12.5% relative 
to the pre-injection values (day 4, 100µg.kg-1 Poly I:C), and the lower limit of the 95% 
confidence interval of the mean difference between zero (no effect of injection) and the 
measured percentage change in tail-flick latency never was greater than 20%.  Thus Poly 
I:C injection did not induce hyperalgesia to a thermal stimulus. 
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Figure 5 shows percentage changes in tail-flick latencies to a noxious thermal challenge 
after injecting rats intradermally either with saline (n = 8), 100 µg.kg-1 Poly I:C (n = 9), 
or 1000 µg.kg-1 Poly I:C (n = 8). The dotted lines represent the level (20%) at which the 
measured percentage change in response latency was considered to be biologically 
significant. 
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ii) Noxious mechanical challenge 
 
 Figure 6 shows percentage changes in escape latencies to a noxious mechanical 
challenge after injecting rats intradermally either with saline, 100 µg.kg-1 Poly I:C, or 
1000 µg.kg-1 Poly I:C. There were no significant changes in escape latencies from pre-
injection values after injection of saline (F(7,7) = 2.02, P = 0.072). However, injection of 
100 µg.kg-1 Poly I:C caused significant mechanical hyperalgesia, but only on days one, 
four and five after injection (F(7,8) = 13.74, P < 0.001). Injection of 1000 µg.kg-1 Poly I:C 
also caused significant mechanical hyperalgesia, but this hyperalgesia started within three 
hours of the injection and was maintained for four days (F(7,7) = 8.12, P < 0.001). On 
average, the escape latency in animals injected with 1000 µg.kg-1 Poly I:C was reduced 
by about 40%. Thus there was a dose-dependent increase in the duration of the 
mechanical hyperalgesia induced by Poly I:C. 
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Figure 6 shows the percentage changes in escape latencies to a noxious mechanical 
challenge after injecting rats intradermally either with saline (n = 8), 100 µg.kg-1 Poly I:C 
(n = 9), or 1000 µg.kg-1 Poly I:C (n = 8). The dotted lines represent the level (20%) at 
which the measured percentage change in response latency was considered to be 
biologically significant.  
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iii) Histology 
 
Figure 7 shows representative samples of tail-skin tissue sections taken from the site of 
either saline, 100 µg.kg-1 Poly I:C, or 1000 µg.kg-1 Poly I:C injection three hours, one 
day, four days and ten days after injection. Irrespective of the injection, all animals 
developed mild inflammation within three hours of injection. However, the inflammation 
had resolved 24 hours later in the saline injected animals. On average, mild inflammation 
was present in tissue samples taken one, four and ten days after injecting rats with 100 
µg.kg-1 Poly I:C.  In rats injected with 1000 µg.kg-1 Poly I:C, the median level of 
inflammation increased from mild, three hours after injection, to moderate on days one 
and four after injection. By day ten only mild inflammation, with fibrosis was present. 
Thus there was a dose-dependent increase in the level of inflammation after Poly I:C 
injection. 
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                   POLY I:C_______ 
                   Saline      100µg/kg         1000µg/kg 
 
3h        
1 day        
    4 day        
  10 day     
 
Figure 7. Inflammatory changes in rats’ tails 3 hours (3h), 1 day, 4 days, and 10 days 
after intradermal injection either with saline (n = 15), 100 µg.kg-1 Poly I:C (n = 15), or 
(J) (K) (L) 
(G) (H) (I) 
(D) (E) (F) 
(A) (B) (C) 
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1000 µg.kg-1 Poly I:C (n = 15). All sections were stained with eosin and haematoxylin, 
and photographs were taken at 100x magnification, with the epidermis orientated at the 
top of the image. Samples taken 3 hours after injection of saline, 100 µg.kg-1 Poly I:C or 
1000 µg.kg-1 Poly I:C all showed the presence of mild inflammation, characterized by the 
presence of neutrophils, lymphocytes and plasma cells (indicated in B). Samples taken 1 
day, 4 days and 10 days after saline injection showed no signs of inflammation, except 
for one sample taken 1 day after saline injection, which showed the presence of moderate 
inflammation. Two samples taken 1 day after injecting rats with 100 µg.kg-1 Poly I:C 
showed the presence of mild inflammation, while severe inflammation was found in one 
sample, as evident by the presence of neutrophils, lymphocytes and plasma cells 
(indicated in E). One day after injection of 1000 µg.kg-1 Poly I:C, mild, moderate and 
severe  inflammation was present in each of the three samples respectively, with necrosis 
being present in the sample with signs of moderate inflammation (indicated in F). Four 
days after 100 µg.kg-1 Poly I:C injection, two samples had no signs of inflammation, and 
one sample had mild inflammation, with lymphocytes and plasma cells present. There 
was moderate inflammation in two samples, and mild inflammation in one sample taken 
4 days after injection of 1000 µg.kg-1 Poly I:C, with the sample shown in the figure 
demonstrating the presence of moderate inflammation with focal fibrinopurulent exudates 
(indicated in I). Mild inflammation with cell infiltrate was evident in all samples taken 10 
days after 100 µg.kg-1 Poly I:C injection. Ten days after injection of 1000 µg.kg-1 Poly 
I:C, two tissue sample showed signs of mild to moderate inflammation with mild fibrosis 
(indicated in L). The histopathology was done at the Kings Mill Hospital. 
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2.3.4. Discussion 
  
I have described the behavioural and histological characteristics of a novel model of 
virus-induced hyperalgesia, produced by infusing a pyrogenic and non-pyrogenic dose of 
Poly I:C intradermally in the rats’ tail. After 1000 µg.kg-1 Poly I:C administration, 
primary mechanical hyperalgesia was induced that started three hours after injection and 
persisted for four days. Injection of the non-pyrogenic 100 µg.kg-1 dose of Poly I:C also 
induced primary mechanical hyperalgesia. However, compared to the response of the               
1000 µg.kg-1 dose, the hyperalgesia took longer to develop, and the response was 
biphasic in nature, such that there was significant hyperalgesia only on day one after 
injection and on days four and five after injection. Histologically, there was a dose-
dependent increase in the inflammatory response at the site of Poly I:C injection, which 
may explain the sustained hyperalgesia in animals injected with the higher dose of Poly 
I:C. Irrespective of the dose of Poly I:C injected, tail-skin tissue still was inflamed after 
the mechanical hyperalgesia had subsided. Surprisingly, neither dose of Poly I:C 
produced significant thermal hyperalgesia. 
 
The absence of thermal hyperalgesia in my study may be a consequence of the method I 
used to test for thermal hyperalgesia. The presence of thermal hyperalgesia was tested for 
using the method described by Gelgor et al (1986), which involves submerging the tail 
into 49ºC water. Other authors who showed that viral antigens induced thermal 
hyperalgesia, such as Milligan and colleagues (2000) who injected gp120 molecules and, 
Fleetwood-Walker and colleague (1999) who inoculated rats with HSV-1, used the 
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Hargreaves test, which measures response latencies to a radiant heat source. Herzberg 
and Sagen (2001) also found the presence of thermal hyperalgesia when using a radiant 
heat source after directly exposing peripheral nerves to gp120. However, differences in 
the ability of different methods of testing for thermal hyperalgesia do exist. For example,  
Weber and colleagues (2005) who also submerged rats’ tails into 49ºC water, found no 
thermal hyperalgesia after incision, but others using a radiant source have found thermal 
hyperalgesia post-operatively. The lack of thermal hyperalgesia in my animals may imply 
that at the site of injection, no sensitisation of primary afferent nociceptors occurred; 
thermal hyperalgesia is believed to be caused by sensitization of Type 1 A-fiber 
mechano-heat-sensitive nociceptors  (Campbell 2005; Meyer 2005). An alternative 
reason for lack of thermal hyperalgesia in my animals is that Poly I:C may simply not 
produce thermal hyperalgesia, an aspect which may need further investigation. Congruent 
with my findings, however, are those of Sasaki et al (2003) who found no thermal 
hyperalgesia in mice infected with Herpes Simplex Virus, even though they used a 
radiant heat source as the thermal stimulus. 
 
Although inflammation is present in my study, no thermal hyperalgesia was identified, 
which is different to other models of inflammatory pain such as carrageenan and 
complete Freund’s adjuvant being injected into the hindpaw (Woolf et al. 1997; Cunha et 
al. 2000). Inflammatory mediators, such as TNF-α and IL-1, are released and act directly 
on receptors, or act indirectly by releasing further inflammatory mediators, such as 
prostaglandins, that act on the neurons themselves (Kidd and Urban 2001; Woolf et al. 
1997). Mechanical hyperalgesia, also has been reported after administration of HIV-1 
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gp120, Herpes Simplex Virus and Varicella-Zoster Virus in both rats and mice (Andoh et 
al. 1995; Fleetwood-Walker et al. 1999; Milligan et al. 2000; Takasaki et al. 2000a). 
Mechanical hyperalgesia may be mediated by chemical signals such as TNF-α and 
prostaglandin E2 that modulate the sensory fibre terminals (Cunha et al. 2000). The 
presence of inflammatory cell infiltrate correlating with the presence of mechanical 
hyperalgesia in the tail, may indicate that in my study, the mechanical hyperalgesia is 
induced by inflammatory mediators, such as TNF-α (Woolf et al. 1997). However, the 
presence of the inflammatory cell infiltrate lasted longer than the hyperalgesia induced by 
the pyrogenic and non-pyrogenic doses of hyperalgesia. I do not know why hyperalgesia 
would resolve despite persistent tissue inflammation. Full elucidation of the underlying 
mechanisms in Poly I:C-induced hyperalgesia will probably require characterization of 
the peripheral and central production of inflammatory cytokines other than Poly I:C 
inoculation.  
 
While I did measure for the presence of primary hyperalgesia, I did not assess whether 
injection of Poly I:C induced secondary mechanical hyperalgesia and was thus unable to 
indicate whether there was any central sensitisation of nociceptive pathways by Poly I:C. 
Central sensitisation involves the augmentation of pain pathways, with input from low-
threshold mechanoreceptors, within the spinal cord (Woolf 2004). Secondary mechanical 
hyperalgesia should be assessed as opposed to secondary thermal hyperalgesia since 
secondary hyperalgesia only exists for mechanical but not for thermal stimuli (Campbell 
2005; Meyer 2005).  
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Dispite the disassociation of inflammation and hyperalgesia observed, both pyrogenic 
and non-pyrogenic doses of Poly I:C produced mechanical hyperalgesia in the tail. The 
non-pyrogenic dose exhibited maximum hyperalgesia on days 4 and 5 after injection. My 
results are similar to other virus models of hyperalgesia where maximum hyperalgesia 
was exhibited on days four to six, peaking on day five after inoculation/injection 
regardless of the virus used (Fleetwood-Walker et al. 1999; Takasaki et al. 2000a; 
Takasaki et al. 2000b). The biphasic nature of the mechanical hyperalgesia observed after 
the administration of the non-pyrogenic in my study is similar to the biphasic 
hyperalgesic response observed after IL-1β administration into the cerebral ventricle 
(Zelenka et al. 2005). However, my study is the first to illustrate viral mechanical 
hyperalgesia following injection of a non-pyrogenic of Poly I:C. 
 
The difference in mechanical hyperalgesia produced by of the pyrogenic and non-
pyrogenic dose of Poly I:C is that the pyrogenic dose produced hyperalgesia which was 
sustained from the third hour after injection until the fourth day after injection. The 
earlier onset of the mechanical hyperalgesia for the pyrogenic dose of Poly I:C may be a 
response to the fever induced by that dose. The 1000 µg.kg-1 Poly I:C dose produced a 
fever starting three hours after intraperitoneal injection or intradermal injection, as in our 
study, and peaking four and a half hours after injection (Fortier et al. 2004). Poly I:C-
induced fever and possibly mechanical hyperalgesia may in part, be mediated by pro-
inflammatory cytokines such as TNF-α and IL-1β. In my study, inflammation as seen by 
histological changes after injection of both the pyrogenic and non-pyrogenic doses of 
Poly I:C, may contribute to the presence of mechanical hyperalgesia. 
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Histological changes obtained after HIV-gp120 administration around a peripheral nerve, 
revealed inflammatory cell invasion into the nerve trunk to be short lasting (5 days), 
suggesting that the initial hyperalgesia and allodynia observed was from the 
inflammatory response, but that the sustained hyperalgesia was mediated by other 
mechanisms (Herzberg and Sagen 2001). In my study, the Poly I:C fever and initial 
mechanical hyperalgesia may be mediated by TNF-α and other inflammatory mediators 
at the site of injection , but the prolonged hyperalgesia may be through centrally mediated 
mechanisms. A cytokine profile along with behavioural and histological data should be 
done not only to corroborate the function of non-inflammatory mechanisms in prolonged 
hyperalgesia but also to ascertain whether a link exists between the fever response, 
behavioural response, and histological changes. 
 
In conclusion, I have successfully developed an animal model of virus-induced 
hyperalgesia using the rat’s tail. Both non-pyrogenic and pyrogenic doses of Poly I:C 
induced primary mechanical hyperalgesia. The model encompasses both pyrogenic and 
non-pyrogenic viruses, and uses the rats’ tail that interferes less with the animals’ 
activity. The described model may be used to further elucidate the pathophysiological 
mechanisms involved with viral infections in general. Understanding these mechanisms 
could yield effective drug treatments against pain associated with viral infections. 
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Chapter 3 
Conclusion 
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The lack of appropriate animal models to better understand the underlying mechanisms of 
viral pain, and the inadequacy of viral pain management are hurdles in dealing with viral 
pain. The acute models of viral pain that have been created have been specific for certain 
viral infections, such as HIV and herpes virus infections, so that any information and 
solutions gathered from these models is only applicable to that specific viral infection. 
Therefore, the objective of my dissertation was to develop a generic model of virus 
induced pain. The synthetic analogue of viral dsRNA, Poly I:C, was used, which may 
enable us to understand the general mechanisms that are associated with viral infections.  
 
In comparison to other virus-specific models, mechanical hyperalgesia observed in my 
study, lasted 5 days at most, where Fleetwood-Walker and colleagues (1999), who used a 
live virus, induced mechanical hyperalgesia that lasted for 33 days. For Milligan and 
colleagues (2000), the mechanical hyperalgesia observed in their study lasted for only 
100 minutes and the thermal hyperalgesia, lasted for 120 minutes. In my study, I 
observed no thermal hyperalgesia, but observed mechanical hyperalgesia that lasted for 
an average of four and a half days (between the pyrogenic and non-pyrogenic dose). 
Therefore, the mechanical hyperalgesia in my model lies between that described by 
Milligan et al. (2001) and Fleetwood-Walker et al. (1999).   
 
The mechanisms responsible for the mechanical hyperalgesia observed in my study may 
in part be due to cytokines which are known to be released by Poly I:C. In truth, Poly 
I:C’s mechanisms for inducing mechanical hyperalgesia may be the basis for 
hyperalgesia observed in other viral-specific models of pain. Since the dose and route of 
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administration is important for fever production after Poly I:C administration, the route of 
administration may be an important factor as well for the mechanical hyperalgesia. My 
findings also provide further evidence that fever and hyperalgesia do not necessarily 
occur concomitantly after an immunological challenge. Thus, my study has been able to 
demonstrate a viral infection that causes hyperalgesia, in rats, with no consequence of 
whether fever is produced or not. Also, the signs I measured after Poly I:C 
administration, in terms of fever and hyperalgesia, mimic general signs and symptoms 
that are associated with the sickness syndrome reported after viral infections such as 
influenza. A cytokine profile during the fever and hyperalgesic responses following Poly 
I:C injection is needed to confirm the role that cytokines may play in both fever and 
hyperalgesia. This profile would also reveal the sequence of cytokine release during the 
responses observed. 
 
The model of virus induced pain described in this dissertation provides the platform for 
future studies on the mechanisms of viral pain. Therefore, for possible future studies, a 
cytokine profile is needed to elucidate the messengers that are responsible for the 
hyperalgesia observed. Also, to better the model, further studies using analgesics need to 
be done.  Indeed, the elucidation of the underlying mechanisms of viral pain could lead to 
the improvement of current therapies and the development of new therapies designed to 
alleviate viral pain in humans. 
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